Company
Every published round Pfizer took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Pfizer has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Pfizer, as distinct from the investments it has made.
Companies Pfizer has backed that another company then bought. An exit for the holding, not a deal Pfizer did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of Pfizer is recorded as having been acquired. | ||||
Companies Pfizer acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Company | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| ResApp | Acquisition | 26 Sep 2022 | $179m | sharecafe.com.au, Techboard, Startup Daily (3 Oct 2022), Startup News (WA), Startup Daily (28 Sep 2022), SmartCompany, @AuManufacturing |
| Name | Role | Sources |
|---|---|---|
| Dr Rochelle Chaiken | Chief Medical Officer (former) | Brandon Capital, Brandon BioCatalyst, @AuManufacturing |
Stories naming Pfizer. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
UQ medtech spin-out Ceretas sold its IPO, raising about $8 million, and now targets a fast-tracked ASX debut; the article also recalls ResApp's 2022 acquisition by Pfizer.
Also kalkine.com.au·Dealroom
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
Profile of scientist-entrepreneur Andrew Wilks tracing his path from cancer research to founding drug developer Cytopia and launching SYNthesis BioVentures, a therapeutics fund that recently secured $30 million from wealthy individuals and family offices.
A $2 million Western Australian government matching grant will help Bridgewest upgrade its Bentley drug-making site, NovaCina, adding production lines and roughly 70 jobs while cutting import dependence.
Profiles three founders: Kismet's Mark Woodland ($4m pre-seed for disability-services software), Forage's Tom Brumskill and Pasha Rayan (job-simulation platform, Series A and B), and Diolog's Amy Benson (self-funded investor-communications startup planning a seed round).
Also Startup Daily
Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.
Vaxxas hires former Pfizer medical executive Dr Rochelle Chaiken as its chief medical officer; the announcement also recounts the biotech's founding financing and later rounds.
Vaxxas has appointed 23-year Pfizer veteran Dr Rochelle Chaiken as chief medical officer; the announcement also recaps the vaccine-patch company's early backing by OneVentures, Brandon Capital and others.
Vaxxas appointed Dr Rochelle Chaiken, a former Pfizer executive, as Chief Medical Officer, and reported positive interim Phase 1 trial results for its needle-free COVID-19 vaccine patch at the Boston biotech convention.
Techboard's September 2022 roundup reports Australian raises led by Morse Micro's $140m Series B, several acquisitions including ResApp Health to Pfizer, fund closes by Telstra Ventures, OIF and Main Sequence, and open raises.
Ignition Lane's weekly tech roundup covering fresh Australian startup raises, new venture funds and closes, a wave of acquisitions, delistings and a liquidation, executive moves, and Canva's product launch.
Also Techboard·Startup Daily
Pfizer has completed its takeover of ASX-listed telehealth diagnostics company ResApp Health for $179 million, with the article recalling the company's 2015 listing, earlier raises and a Gates Foundation grant.
Pfizer has completed its purchase of Brisbane digital health company ResApp Health for $179 million, doubling its per-share offer after an April bid for the ASX-listed cough-diagnosis startup.
Also SmartCompany·Startup Daily·Startup Daily·Techboard·Startup News (WA)·sharecafe.com.au
Pfizer has bid $100m for ResApp, a Brisbane healthtech firm whose app diagnoses respiratory conditions from coughs; its board backs the deal, and the piece recalls a 2021 $5.5m raise under Fidelity International's lead.
Also Startup Daily
Profile of Australian biotech Spinifex Pharmaceuticals and its neuropathic pain drug EMA401, covering phase II trials, the science behind its AT2 approach, and its venture backers as it weighs a future series C.